Torrent Pharmaceuticals has emerged as the frontrunner in India’s rapidly expanding generic semaglutide market, capturing nearly 38 percent market share within just one month of launch. The company’s strong start follows the expiry of Novo Nordisk’s patent for semaglutide in India at the end of March, which opened the door for multiple domestic pharmaceutical companies to introduce lower-cost generic alternatives for diabetes and weight management.
Generic Semaglutide Market Crosses ₹44 Crore in April
More than a dozen Indian pharmaceutical companies launched generic versions of semaglutide in April 2026. Collectively, these products generated nearly ₹44 crore in sales during the month. Torrent Pharma led the market with sales of around ₹17 crore, significantly outperforming competitors such as Zydus Lifesciences, Dr. Reddy’s Laboratories and Lupin Limited, which recorded sales of approximately ₹4 crore each. Meanwhile, Alkem Laboratories and Eris Lifesciences posted sales of around ₹3.4 crore each, while Sun Pharmaceutical Industries and USV Private Limited generated nearly ₹2.3 crore each.
Oral Semaglutide Gives Torrent Competitive Edge
Industry experts attribute Torrent Pharma’s rapid market penetration to its dual-format launch strategy. The company is currently the only Indian pharmaceutical player offering generic semaglutide in both oral tablet and injectable formulations. According to Aasim Maldar, consultant endocrinologist and diabetologist at PD Hinduja Hospital, patient preference for oral medication has played a major role in driving demand. “Torrent’s early lead appears to be driven by oral semaglutide,” Maldar informed.
India’s Weight-Loss Drug Market Expands Rapidly
India’s anti-obesity and weight-management drug market is witnessing strong growth as global blockbuster drugs such as Ozempic, Wegovy and Mounjaro enter the market alongside lower-cost generic alternatives. A report published by Forbes India in April 2026 highlighted that rising obesity levels, increasing social media influence and improved affordability are accelerating consumer demand for GLP-1 weight-loss therapies.
Anti-Obesity Drug Sales More Than Double
India’s anti-obesity drug market recorded exceptional growth in 2025. According to a report by Business Standard, sales surged 115 per cent year-on-year, driven by the growing popularity of injectable GLP-1 agonists such as semaglutide and tirzepatide. The overall market size expanded to nearly ₹1,230 crore in 2025, compared with ₹571 crore in 2024, reflecting rising awareness of obesity management and increasing adoption of newer therapies.
GLP-1 Drugs Gain Ground in Diabetes and Obesity Care
GLP-1 agonists are a class of medications designed to regulate blood sugar levels, slow stomach emptying and increase satiety. As a result, they help patients achieve better glucose control while supporting weight loss in individuals with type-2 diabetes and obesity. As reported by outlookbusiness.com, despite their growing popularity, GLP-1 therapies currently account for only around five percent of India’s overall anti-diabetes market, which serves more than 100 million people. Industry analysts expect this share to rise steadily as affordability improves and generic competition intensifies.
